Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

Given this risk, we thought we'd take a look at whether SpringWorks Therapeutics (NASDAQ:SWTX) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...

Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a med ...

Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Springworks Therapeutics. Currently, the analyst consensus on Sarepta ...

On Wednesday, SpringWorks Therapeutics Inc (SWTX) stock saw a modest uptick, ending the day at $30.48 which represents a slight increase of $0.35 or 1.16% from the prior close of $30.13. The stock ...

5.9% of Immunovant shares are held by company insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that ...

STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...

STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...